1. Home
  2. COYA vs ICCC Comparison

COYA vs ICCC Comparison

Compare COYA & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Coya Therapeutics Inc.

COYA

Coya Therapeutics Inc.

HOLD

Current Price

$4.61

Market Cap

110.0M

Sector

Health Care

ML Signal

HOLD

Logo ImmuCell Corporation

ICCC

ImmuCell Corporation

HOLD

Current Price

$9.84

Market Cap

93.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COYA
ICCC
Founded
2020
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
110.0M
93.1M
IPO Year
2022
1995

Fundamental Metrics

Financial Performance
Metric
COYA
ICCC
Price
$4.61
$9.84
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$15.80
N/A
AVG Volume (30 Days)
89.9K
25.7K
Earning Date
05-08-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
53.85
EPS
N/A
0.41
Revenue
$7,945,753.00
$26,493,169.00
Revenue This Year
N/A
N/A
Revenue Next Year
$763.10
N/A
P/E Ratio
N/A
$24.15
Revenue Growth
123.57
51.64
52 Week Low
$3.71
$4.52
52 Week High
$7.75
$12.10

Technical Indicators

Market Signals
Indicator
COYA
ICCC
Relative Strength Index (RSI) 49.84 44.98
Support Level $4.45 $9.36
Resistance Level $5.19 $10.75
Average True Range (ATR) 0.24 0.33
MACD -0.02 0.01
Stochastic Oscillator 36.11 46.42

Price Performance

Historical Comparison
COYA
ICCC

About COYA Coya Therapeutics Inc.

Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.

About ICCC ImmuCell Corporation

ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.

Share on Social Networks: